Evidence map›Paper›PMID 30364635›Full record

ArticleMolecular therapy oncolytics2018

Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma.

Michael P Phelps, Heechang Yang, Shivani Patel, Masmudur M Rahman, Grant McFadden, Eleanor Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Targeting Cancer with CRISPR/Cas9-Based Therapy.International journal of molecular sciences · 2022
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Gene Editing Thumbs a Ride with Oncolytic Virotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2020
    Article
  19. Review
  20. Oncolytic Virotherapy with Myxoma Virus.Journal of clinical medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael P PhelpsDepartment of Pathology, University of Washington, Seattle, WA 98195, USA.
Heechang YangDepartment of Pathology, University of Washington, Seattle, WA 98195, USA.
Shivani PatelDepartment of Pathology, University of Washington, Seattle, WA 98195, USA.
Masmudur M RahmanBiodesign Center for Immunotherapy, Vaccines and Virotherapy, Arizona State University, Tempe, AZ 85281, USA.
Grant McFaddenBiodesign Center for Immunotherapy, Vaccines and Virotherapy, Arizona State University, Tempe, AZ 85281, USA.
Eleanor ChenDepartment of Pathology, University of Washington, Seattle, WA 98195, USA.

Funding

Characterizing Histone Deacetylases in RhabdomyosarcomaR01CA196882 · NCI · UNIVERSITY OF WASHINGTON · PI CHEN, ELEANOR Y · 2016 to 2020
$1.6M
NCI NIH HHS R01 CA196882
6 · The paper itself

Abstract

Aberrant activation of the receptor tyrosine kinase-mediated RAS signaling cascade is the primary driver of embryonal rhabdomyosarcoma (ERMS), a pediatric cancer characterized by a block in myogenic differentiation. To investigate the cellular function of activated RAS signaling in regulating the growth and differentiation of ERMS cells, we genetically ablated activated

Indexed as

cancer gene therapyCRISPRmyxomaoncolytic virusRASrhabdomyosarcoma

Identifiers

PMID30364635
PMCPMC6197336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.